Articles for author: Ron Finklestien

January 8, 2024

Ron Finklestien

2024 Preview: Latin America VC Industry

This article is part of the LatAm Tech Weekly Series, written by Julia De Luca and powered by Nasdaq. Through Nasdaq’s global network, we partner with Latin American companies to support their entire business lifecycle to elevate their brand and access the global markets. Learn more about Latin American Listings here. I’m excited to greet you for the first LatAm Tech Weekly of 2024. This week’s edition is quite special as I delve into an insightful analysis offering a glimpse into the venture market of the current year. But, before we delve into that, let me provide a quick recap of my action-packed 2023.

January 8, 2024

Ron Finklestien

Acadia Healthcare: A Prescription for Portfolio Success Why Acadia Healthcare is a Prescription for Portfolio Success

Acadia Healthcare Company, Inc. ACHC is strategically poised for growth, driven by increasing admissions and expansion in Medicare, Medicaid, and commercial businesses. The growing demand for its acute inpatient psychiatric facilities, specialty treatment facilities, and comprehensive treatment centers serves as a significant revenue driver for the company. With a market capitalization of $7.3 billion, Acadia Healthcare operates as a prominent behavioral healthcare services provider in the United States and Puerto Rico. Due to solid prospects, this currently Zacks Rank #2 (Buy) stock is worth investing in at the moment. In this analysis, we’ll explore the growth drivers and estimates and

January 8, 2024

Ron Finklestien

Breaking News: Dada Nexus Limited Reveals Revenue Overstatement Revenue Overstatement Causes Dada Nexus Stock to Plummet

The Revelations: Dada Nexus Limited DADA shocked investors when it disclosed suspicious practices that led to potential revenue overstatement in its online advertising and marketing services in 2023 during a routine internal audit. The company further added that such overstatement had taken a toll on the credibility of its fourth-quarter and 2023 guidance, leaving stakeholders in a state of uncertainty. The announcement reverberated in the market, causing Dada Nexus shares to plummet amidst heavy trading volume. Trading data from Benzinga Pro indicates that over 11.7 million shares exchanged hands during the session, a stark contrast to the stock’s 100-day average

January 8, 2024

Ron Finklestien

Investors Eye AKYA, DRTS, and TRUP as Top Momentum Stocks

A trio of stocks is turning heads today with their impressive buy rank and robust momentum. The allure of starting off 2024 with these potential high-flyers is palpable, and investors are poised to dive into Akoya Biosciences, Alpha Tau Medical Ltd., and Trupanion, Inc. Let’s take a closer look at why these picks are creating such a buzz in the market. Akoya Biosciences, Inc.: Breaking Scientific Barriers Akoya Biosciences, Inc. AKYA has been making waves in the life sciences technology sector, earning a Zacks Rank #1. In the past 60 days, the Zacks Consensus Estimate for its current-year earnings has

January 8, 2024

Ron Finklestien

Examining the Potential Impact of the Proposed Bitcoin ETF Challenging Assumptions Around the New Bitcoin ETF

The SEC is on the cusp of delivering their decision on the proposed spot bitcoin ETF. Analysts have been quick to predict an inevitable approval. The anticipation has been a driving force behind the significant surges in BTC/USD. With bitcoin reaching around $45k, the disappearance of doomsayers, who previously prophesied its demise, is indeed curious. Contrary to expectations, a bearish outlook might be sensible amidst the current disappearance of naysayers. The looming approval of a spot ETF could potentially reveal an “Emperor has no clothes” moment in the market, leading to a deep reconsideration of the assumptions underpinning the recent

January 8, 2024

Ron Finklestien

Five Cannabis Stocks with Potential for Growth and Stability

Confidence Amidst Market Upswing The first week of 2024 witnessed substantial stock price appreciation for the majority of the 30 stocks ranked weekly by Viridian Capital Advisors. Notably, the MSOS ETV surged by 12.84%, marking the sharpest uptick since the HHS announcement at the end of August. Surprisingly, the surge was not catalyzed by any specific news—just a market eager to believe following confirmation from the DEA that they are studying the issue of rescheduling. Despite optimism, Viridian Capital Advisors indicated a likelihood of DEA moving to schedule 3 to eliminate 280e benefits, but expressed skepticism about the possibility of

January 8, 2024

Ron Finklestien

Insights into Ardelyx Stock Movement Insights into Ardelyx Stock Movement

Ardelyx, Inc. ARDX shares are trading higher Monday after the company provided a strategic business update. Here’s a look at what’s going on. The Strategic Update: Ardelyx, Inc. released a business update on Monday, predicting that its FDA-approved IBS treatment, Ibsrela, is poised to transcend the market with over ten percent share at its zenith, projecting to yield over $1.0 billion in annual U.S. net product sales revenue before the patent term expiration. Moreover, the company forecasts 2024 U.S. net product sales revenue for Ibsrela to reach between $140 million and $150 million for the full year. Speaking on the

January 8, 2024

Ron Finklestien

Electronics Semiconductor Stocks For the Win 4 Electronics Semiconductor Stocks to Consider

The global macroeconomic environment and market volatility have put immense pressure on the Zacks Electronics – Semiconductors industry. Geo-political tensions, forex challenges, and inflationary pressures have all made a significant impact on the industry’s outlook. The industry has, however, seen several players like Advanced Micro Devices (AMD), ASE Technology (ASX), Cirrus Logic (CRUS) and QuickLogic (QUIK) benefit from the rising demand for consumer electronic devices and innovative technological solutions. The Zacks Electronics – Semiconductors industry caters to various end-markets and provides cutting-edge semiconductor technologies, packaging and test services, and intelligent and connected products. These companies are investing heavily in research

January 8, 2024

Ron Finklestien

Canoo Inc. Reports Purchase of New Manufacturing Assets Driving Stock Surge Canoo Inc. Reports Purchase of New Manufacturing Assets Driving Stock Surge

Revving Up Production Canoo Inc GOEV shares are trading higher. The company on Monday reported the purchase of new manufacturing assets. What’s Happening: Canoo announced the purchase of manufacturing assets “at dramatically reduced prices” to scale production at its Oklahoma City facility. The assets, including robotics and controls processing equipment for building vehicle cabins, were procured at discounted prices of over 80% of estimated value. “While many companies invested in capital equipment prematurely, we continue to phase our investment with our growth,” said Ramesh Murthy, Canoo’s chief accounting officer. “These opportunities to acquire assets at significantly discounted prices have allowed us to further reduce our 2023

January 8, 2024

Ron Finklestien

Boeing and Spirit AeroSystems Plunge – A Financial Rollercoaster Boeing and Spirit AeroSystems Plunge: A Financial Rollercoaster

Listen below or on the go on Apple Podcasts and Spotify Plunge of Shares Shares of Boeing and Spirit AeroSystems have plummeted after a mid-air incident sent shockwaves through the aerospace industry. Boeing is down 8% pre-market due to a safety issue related to one of its plane models. A door plug on Alaska Airlines Flight 1282 blew out, causing the cabin to rapidly depressurize, only 6 minutes after takeoff. Although the plane landed back safely and no serious injuries were reported, the FAA ordered certain Boeing 737 MAX 9 planes to be grounded after the incident. Notably, the part